In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Science

Gene Therapy’s Next Target: Our Microbes

CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years. 

Innovation Gene Therapy

‘AI-volution’ In Life Sciences? Unveiling Trends in Worldwide Patent Filings

Computing, including AI, applied to life sciences is undeniably a rapidly growing area, driven by significant investment, recent technological advancements and heightened public interest. A look at published patents from 2014 to 2023 reveals trends in patent filings across various life sciences sectors and highlights geographical hotspots.

Patents Companies

How Cellino’s Cassette Technology Will Impact Regenerative Medicine

Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.

Rising Leaders Regenerative Medicine

Rezo’s Platform Could ‘Fundamentally Shift’ Drug Discovery

Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.

New Science C-Suite Speaks

Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline

Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.

Rising Leaders Oncology

Synthetic Biology Matures, Promising Affordable And Personalized Treatments

Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.

Innovation Artificial Intelligence

Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics

CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.

Rising Leaders Clinical Trials

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Market Access Gene Therapy

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

Business Strategies Commercial

In Vivo’s 2024 Rising Leaders

The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

Rising Leaders Leadership

Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy

Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”

Clinical Trials Innovation

CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made

Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.

Innovation Market Intelligence

Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. 

Metabolic Disorders Clinical Trials

First TIL Cell Therapy Approval Paves Way For Next Generation

Iovance Biotherapeutics' Amtagvi (lifileucel) received approval from the US FDA in February, marking a truly pivotal milestone in the field of solid tumor therapy for certain adult patients with unresectable or metastatic melanoma. As the first approved tumor infiltrating lymphocyte (TIL) therapy, it is set to expedite the regulatory pathway for next-generation products.

Cancer Approvals

Understanding How To Develop BTK Inhibitors In MS Is Evolving

Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.

Clinical Trials Drug Safety

Building A Biotech: Exploring ILC’s Hybrid Interferon Platform

Non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics’ platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

Business Strategies StartUps and SMEs